<?xml version='1.0' encoding='utf-8'?>
<document id="31740393"><sentence text="Drug-drug interaction between crizotinib and entecavir via renal secretory transporter OCT2."><entity charOffset="30-40" id="DDI-PubMed.31740393.s1.e0" text="crizotinib" /><entity charOffset="45-54" id="DDI-PubMed.31740393.s1.e1" text="entecavir" /><pair ddi="false" e1="DDI-PubMed.31740393.s1.e0" e2="DDI-PubMed.31740393.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s1.e0" e2="DDI-PubMed.31740393.s1.e1" /></sentence><sentence text="Both entecavir and crizotinib are substrates of organic cation transporter 2 (OCT2)"><entity charOffset="5-14" id="DDI-PubMed.31740393.s2.e0" text="entecavir" /><entity charOffset="19-29" id="DDI-PubMed.31740393.s2.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s2.e0" e2="DDI-PubMed.31740393.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s2.e0" e2="DDI-PubMed.31740393.s2.e1" /></sentence><sentence text=" The aim of present study was to investigate the mechanisms of drug interactions between these two drugs" /><sentence text=" Kinetic analysis of entecavir on crizotinib uptake was conduct"><entity charOffset="21-30" id="DDI-PubMed.31740393.s4.e0" text="entecavir" /><entity charOffset="34-44" id="DDI-PubMed.31740393.s4.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s4.e0" e2="DDI-PubMed.31740393.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s4.e0" e2="DDI-PubMed.31740393.s4.e1" /></sentence><sentence text=" Plasma concentration of crizotinib in rats and lung cancer patients, uptake of crizotinib in kidney slices and OCT2 transfected cells, were determined by LC-MS/MS"><entity charOffset="25-35" id="DDI-PubMed.31740393.s5.e0" text="crizotinib" /><entity charOffset="80-90" id="DDI-PubMed.31740393.s5.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s5.e0" e2="DDI-PubMed.31740393.s5.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s5.e0" e2="DDI-PubMed.31740393.s5.e1" /></sentence><sentence text=" The clinical pharmacokinetic interactions and impact on adverse reaction of crizotinib in lung cancer patients were investigated"><entity charOffset="77-87" id="DDI-PubMed.31740393.s6.e0" text="crizotinib" /></sentence><sentence text=" Steady-state through concentration of crizotinib was measured"><entity charOffset="39-49" id="DDI-PubMed.31740393.s7.e0" text="crizotinib" /></sentence><sentence text=" The crizotinib-related adverse reactions were recorded in lung cancer patients with and without entecavir"><entity charOffset="5-15" id="DDI-PubMed.31740393.s8.e0" text="crizotinib" /><entity charOffset="97-106" id="DDI-PubMed.31740393.s8.e1" text="entecavir" /><pair ddi="false" e1="DDI-PubMed.31740393.s8.e0" e2="DDI-PubMed.31740393.s8.e0" /><pair ddi="true" e1="DDI-PubMed.31740393.s8.e0" e2="DDI-PubMed.31740393.s8.e1" /></sentence><sentence text=" Entecavir and 1-methyl-4-phenylpyridinium iodide significantly inhibited the uptake of crizotinib in kidney slices"><entity charOffset="1-10" id="DDI-PubMed.31740393.s9.e0" text="Entecavir" /><entity charOffset="15-49" id="DDI-PubMed.31740393.s9.e1" text="1-methyl-4-phenylpyridinium iodide" /><entity charOffset="88-98" id="DDI-PubMed.31740393.s9.e2" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s9.e0" e2="DDI-PubMed.31740393.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s9.e0" e2="DDI-PubMed.31740393.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31740393.s9.e0" e2="DDI-PubMed.31740393.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31740393.s9.e1" e2="DDI-PubMed.31740393.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31740393.s9.e1" e2="DDI-PubMed.31740393.s9.e2" /></sentence><sentence text=" Kinetic constants for crizotinib uptake by OCT2 were Km 1"><entity charOffset="23-33" id="DDI-PubMed.31740393.s10.e0" text="crizotinib" /></sentence><sentence text="16 ± 0" /><sentence text="26 µM, Vmax 12" /><sentence text="05 ± 0" /><sentence text="53 µmol/min mg-1 protein and Ki 9" /><sentence text="711 nM" /><sentence text=" Entecavir can inhibit crizotinib transport by OCT2 in kidney"><entity charOffset="1-10" id="DDI-PubMed.31740393.s16.e0" text="Entecavir" /><entity charOffset="23-33" id="DDI-PubMed.31740393.s16.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s16.e0" e2="DDI-PubMed.31740393.s16.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s16.e0" e2="DDI-PubMed.31740393.s16.e1" /></sentence><sentence text=" Co-administration of entecavir significantly reduced the elimination of crizotinib in rats"><entity charOffset="22-31" id="DDI-PubMed.31740393.s17.e0" text="entecavir" /><entity charOffset="73-83" id="DDI-PubMed.31740393.s17.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s17.e0" e2="DDI-PubMed.31740393.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s17.e0" e2="DDI-PubMed.31740393.s17.e1" /></sentence><sentence text=" In lung cancer patients, the steady-state AUCss of crizotinib increased approximately 1"><entity charOffset="52-62" id="DDI-PubMed.31740393.s18.e0" text="crizotinib" /></sentence><sentence text="2 fold (p &lt; 0" /><sentence text="05) but clearance was decreased by approximately 15% in the presence of entecavir"><entity charOffset="72-81" id="DDI-PubMed.31740393.s20.e0" text="entecavir" /></sentence><sentence text=" Steady-state through concentration of crizotinib significantly increased 1"><entity charOffset="39-49" id="DDI-PubMed.31740393.s21.e0" text="crizotinib" /></sentence><sentence text="3-fold when co-administrated with entecavir (p&gt;0"><entity charOffset="34-43" id="DDI-PubMed.31740393.s22.e0" text="entecavir" /></sentence><sentence text="001)" /><sentence text=" Co-medication of entecavir significantly (p &lt; 0"><entity charOffset="18-27" id="DDI-PubMed.31740393.s24.e0" text="entecavir" /></sentence><sentence text="05) increased the risks of vision disorders, diarrhea and vomiting 1" /><sentence text="6-, 2" /><sentence text="3- and 1" /><sentence text="8-fold" /><sentence text=" Entecavir could increase the exposure and reduce the elimination of crizotinib in lung cancer patients"><entity charOffset="1-10" id="DDI-PubMed.31740393.s29.e0" text="Entecavir" /><entity charOffset="69-79" id="DDI-PubMed.31740393.s29.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s29.e0" e2="DDI-PubMed.31740393.s29.e0" /><pair ddi="false" e1="DDI-PubMed.31740393.s29.e0" e2="DDI-PubMed.31740393.s29.e1" /></sentence><sentence text=" Moreover, the presence of entecavir could significantly increase the incidences of adverse reaction of crizotinib"><entity charOffset="27-36" id="DDI-PubMed.31740393.s30.e0" text="entecavir" /><entity charOffset="104-114" id="DDI-PubMed.31740393.s30.e1" text="crizotinib" /><pair ddi="false" e1="DDI-PubMed.31740393.s30.e0" e2="DDI-PubMed.31740393.s30.e0" /><pair ddi="true" e1="DDI-PubMed.31740393.s30.e0" e2="DDI-PubMed.31740393.s30.e1" /></sentence><sentence text="" /></document>